Featured Articles

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Datroway (datopotamab deruxtecan or Dato-DXd) for the treatment of adult patients with locally advanced…
Read More...

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the European Commission (EC) approved VYVGART…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) as a pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1.…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of…
Read More...

Eli Lilly and Company and Verve Therapeutics, Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for…
Read More...

Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies, through their respective subsidiaries, have entered a strategic…
Read More...

 BioNTech SE and CureVac N.V. announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor, NUBEQA (darolutamide), for the treatment of adult patients with…
Read More...

Regeneron Pharmaceuticals, Inc. announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and…
Read More...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease,…
Read More...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically…
Read More...

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational…
Read More...

Biogen Inc. and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announced a strategic collaboration to…
Read More...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the U.S. Food and Drug Administration (FDA) has accepted for review…
Read More...

Eli Lilly and Company and SiteOne Therapeutics, Inc. announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor…
Read More...

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in…
Read More...

UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world’s largest enterprises, announced a strategic collaboration…
Read More...